, >5=0) predicted the probability of ICH growth (ranging from 3.4% for 0 point to 85.8% for 24 points) with good discrimination (C-statistic, 0.73) and calibration (Hosmer-Lemeshow P=0.82) in INTERACT1. Conclusions-The simple BRAIN score predicts the probability of hematoma growth in ICH. This could be used to improve risk stratification for research and clinical practice. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT00226096 and NCT00716079.
C linically significant growth of spontaneous intracerebral hemorrhage (ICH) occurs in about one third of patients who are scanned within 3 hours of symptom onset, but the proportion decreases with time thereafter.
1,2 ICH growth is an important independent predictor of clinical deterioration and outcome. [3] [4] [5] [6] Because of its influence on outcome, an ability to accurately predict ICH growth could influence decisionmaking in clinical management, for example in stratifying patients for surgery and in the design of randomized trials of medical interventions aimed at improving outcomes.
Several associations with the occurrence of ICH growth have been replicated, including larger ICH volume, 2,7 earlier presentation after symptom onset, 1,2 use of oral anticoagulant drugs, 8, 9 and the presence of a spot sign on computed tomographic angiography (CTA). 10 Many other individual associations have been described, but the small sample size of many of these studies has often limited the ability to perform multivariable analyses adjusted for known confounders and associations with ICH growth. One recent study with sufficient power was able to develop and validate a prediction model (which included warfarin anticoagulation use, presence of the CTA spot sign, shorter time to computed tomography [CT] , and baseline ICH volume), 11 but the retrospective analysis and use of CTA and repeat brain imaging only whenever concern Background and Purpose-We developed and validated a simple algorithm to predict the risk of hematoma growth in acute spontaneous intracerebral hemorrhage (ICH) to better inform clinicians and researchers in their efforts to improve outcomes for patients. Methods-We analyzed data from the computed tomography substudies of the pilot and main phases of the Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trials (INTERACT1 and 2, respectively). The study group was divided into a derivation cohort (INTERACT2, n=964) and a validation cohort (INTERACT1, n=346). Multivariable logistic regression was used to identify factors associated with clinically significant (≥6 mL) increase in hematoma volume at 24 hours after symptom onset. A parsimonious risk score was developed on the basis of regression coefficients derived from the logistic model. Results-A 24-point BRAIN score was derived from INTERACT2 (C-statistic, 0.73) based on baseline ICH volume (mL per score, ≤10=0, 10-20=5, >20=7), recurrent ICH (yes=4), anticoagulation with warfarin at symptom onset (yes=6), intraventricular extension (yes=2), and number of hours to baseline computed tomography from symptom onset (≤1=5, 
Methods

Participants
The design of the INTERACT studies have been described in detail elsewhere. [12] [13] [14] In brief, these were international, multicenter, open, assessor-blind, randomized controlled studies in which adult patients with mainly mild-moderate severity, acute spontaneous ICH, and elevated systolic blood pressure (BP; ≥150 to ≤220 mm Hg) were randomly assigned to intensive (target systolic BP <140 mm Hg) or guideline-recommended BP management (systolic BP <180 mm Hg) within 6 hours of ICH symptom onset. 
Procedures
Demographic and clinical characteristics were recorded at the time of enrollment. Stroke severity was measured using the Glasgow Coma Scale and National Institutes of Health Stroke Scale at baseline, 24 hours, and at day 7 (or earlier on discharge from hospital). In predefined CT substudies, there were 346 and 964 patients of INTERACT1 and 2, respectively, who also underwent brain CT at 24 hours after randomization. For each CT scan, uncompressed digital CT images were collected in DICOM format identified only with the patient's unique study number. ICH volumes were calculated centrally, and blind to clinical data, treatment, and date and sequence of scan, using computer-assisted multisliceplanimetric and voxel threshold techniques in MIStar version 3.2 (Apollo Medical Imaging Technology). For the small number of CT scans received as digital images or plain films, ICH volume was measured manually using the ABC/2 method. 5 In INTERACT1, 2 trained neurologists performed the measurements and their inter-reader reliability was tested by reanalysis of ICH volume on 10% of CT scans (intraclass correlation coefficient 0.97 [95% confidence interval, 0.95-0.98]). INTERACT2 included several trained imaging scientists and inter-reader reliability was checked by periodic reanalysis of 15% of the scans reviewed by each scientist against a gold standard single neurologist to avoid drift (intraclass correlation coefficient, 0.92 for total hematoma volume and 0.96 after removing outlier data with total volumes >50 mL).
Clinically significant ICH growth was defined as an absolute growth of ≥6mL from baseline to 24 hours, as defined elsewhere as indicating both a clinically significant and average degree of growth in a broad range of ICH patients. 3, 6, 15 Other definitions used were relative growth of >33%, and relative growth >33% or absolute growth of ≥6 mL.
Statistical Analysis
Logistic regression was used to investigate associations with ICH growth in the INTERACT2 CT substudy development cohort. Significant predictors from the univariate analysis and nonsignificant variables chosen for their potential clinical relevance were tested for their association with ICH growth in a multivariable model. We reduced the full model by successively removing the nonsignificant covariates until all the remaining predictors remained statistically significant (P<0.05).
Collinearity and interaction between variables were checked. We used regression coefficients from the model to generate point scores for predicting the probability of ICH growth. 15, 16 We tested the model in the INTERACT1 CT substudy validation cohort. Performance of the final prediction model was assessed using the area under the receiver-operating characteristic curve and concordance C-statistic for discriminative ability, and the Hosmer-Lemeshow goodness-of-fit statistic for calibration using fifths of the fitted risk values.
17 P<0.05 was considered statistically significant in all tests. All analyses were performed using SAS version 9.3 (SAS institute, Cary, NC).
Results
All 964 patients in the INTERACT2 substudy, of whom 181 (18.8%) developed clinically significant ICH growth according to our definition of ≥6mL, were included in the development data set ( Table 1 ). All 346 patients in the INTERACT1 CT substudy (43 [12. 4%] developed significant ICH growth) were included in the validation data set ( Table 2) . Table 1 shows the univariate analysis, where larger baseline ICH volume, recurrent ICH, anticoagulation with warfarin at onset, the presence of intraventricular hemorrhage, fewer hours from symptom onset to baseline CT, and non-Chinese race were significantly associated with ICH growth. These variables were included as covariates in a multivariable logistic regression model, into which other potentially clinically relevant variables were also forced (age, sex, diabetes mellitus, deep location of ICH, and randomization to intensive BP-lowering treatment). After successively removing nonsignificant covariates from the multivariable model, only baseline ICH volume (B), recurrent ICH (R), anticoagulation with warfarin at onset (A), intraventricular hemorrhage (I), and number of hours to baseline CT from onset (N) remained in the final multivariable model (Table 2) ; no collinearity and interaction were found.
An equation was derived from the multivariable model ( Figure I in the online-only Data Supplement) to estimate the probabilities of developing ICH growth by 24 hours after onset. Regression coefficients from the final model (Table I in the online-only Data Supplement) were used to develop the BRAIN prediction algorithm scoring system (Figure 1) . The median estimated probability of ICH growth was 16.4% (interquartile range, 7.7%-27.2%), with a range from 3.4% (minimum score of 0) to 85.8% (maximum score of 24). The model had good discriminative ability (C-statistic, 0.73; Figure II in the online-only Data Supplement).
The model demonstrated good discrimination (C-statistic, 0.73; Figure II in the online-only Data Supplement) and calibration (Hosmer-Lemeshow χ 2 statistic 4.35; P=0.82) in the independent INTERACT1 data set, where the median probability of ICH growth was estimated to be 9.3% (interquartile range, 5.1%-16.6%). Predicted and observed probabilities of ICH growth in the validation data set corresponded well to over one fifth of predicted probability (Figure 2) .
When significant growth was defined as relative growth >33%, only 2 significant variables were identified in univariate analysis-baseline ICH volume and number of hours from onset to baseline CT-which did not allow development of a model. Similarly, using a definition of ≥6 mL or >33% produced on 2 significant variables-anticoagulation with warfarin at onset and number of hours to baseline CT from onset-which was not comprehensive enough to compose a predictive model.
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Discussion
We developed a simple BRAIN prediction model for estimating the probability of ICH growth using characteristics within the INTERACT2 study that can be routinely assessed in clinical practice. The model demonstrated good discriminative ability and was well calibrated when independently validated in the INTERACT1 data set. The components of the BRAIN prediction model are pathophysiologically plausible. In particular, a larger baseline ICH may reflect multiple bleeding points from arteries or arterioles or under high systemic arterial pressure with further induction of perilesional hemorrhage. 18 Because ICH is a dynamic illness, the earlier a patient is first scanned, the greater the probability of later demonstrating ICH growth. It is also recognized that patients who have been taking warfarin anticoagulation at the time of ICH experience more prolonged bleeding, 8, 19 which may persist beyond 24 hours, 8 and result in larger ICH volumes at both presentation and on future assessment. 8, 20 In regard to intraventricular hemorrhage, this not only indicates more active hemorrhage but potentially also of more activate inflammatory cytokines and altered systemic homeostatic/fibrinolytic pathways, which may in turn lead to a coagulopathic state that further increases the risk of ICH growth. 21 Finally, patients with recurrent ICH are likely to have more severe underlying chronic small vessel cerebrovascular disease, 22 predisposing them to larger and more rapid growth in ICH. 23 The strongest factors for ICH growth are the presence of warfarin anticoagulation (6 points), large baseline ICH (>20 mL, 7 points) and a short time from onset to first CT (<3 hours, ≈4 points), which alone will have an expected hematoma growth of ≈10%; when combined, however, this outcome occurs in over 50%. Using all variables in this risk model, a patient presenting within 3 hours of onset of a firstever small supratentorial ICH without intraventricular hemorrhage or prior anticoagulation would have risk of significant hematoma growth of <1 in 10 (8%). Our model may be appropriate for subject selection and risk adjustment in future clinical trials. It may also be useful for triaging patients for more intensive monitoring or intervention.
The strengths of the BRAIN prediction model lie in being derived from a large sample, prospectively collected data, and timely and complete baseline and 24-hour CT acquisition. In addition, the model is based on simple routinely available variables, which underwent independent validation in a large international data set, despite some of the differences in baseline characteristics and directions of association with ICH growth in some subgroups (Table 3) . Finally, our approach adhered to the recent PROGRESS statement on prognostic model research. 24 We recognize, however, that there are several limitations. To begin with, we only included ICH patients within 6 hours after the onset of symptoms (although hematoma growth is known to be less likely to occur after this time) and associated elevated systolic BP (although high blood BP is present in over 75% of patients with primary ICH 25, 26 and baseline BP was not higher than in other prediction models).
11,27 Second, we did not perform CTA to assess whether the spot sign-which seems to be a strong and independent predictor of ICH growth 10, 28 -added further predictive power to our model. However, the C-statistic of a recently published ICH growth prediction model that included CTA spot sign was 0.72 for the development cohort and 0.77 for the validation cohort, 11 which is comparable with the BRAIN score. Finally, as over 90% of subjects were Chinese in the validation cohort, the BRAIN score may need to be further validated in other ethnic populations. 
Stroke
February 2015
In conclusion, we developed and independently validated a simple prediction score for ICH growth, which can be easily assessed and implemented across a range of healthcare settings. In particular, it could be used for shared clinical decision-making in many areas of the world where CTA is not readily available or routinely performed for acute ICH.
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